Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study

P. Ambery, T. W. Donner, N. Biswas, J. Donaldson, J. Parkin, C. M. Dayan

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes: DEFEND-2, a randomized, placebo-controlled, double-blind, multi-centre study'. Together they form a unique fingerprint.

Medicine & Life Sciences